Barclays Upgrades GlaxoSmithKline (GSK) to Overweight
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $52.88 +3.38%
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Barclays upgraded GlaxoSmithKline (NYSE: GSK) from Equalweight to Overweight.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $44.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
- Nomura/Instinet Upgrades Shenzhen T&S Communication (300570:CH) to Buy
- Morgan Stanley Upgrades Suncor Energy (SU) to Overweight
Create E-mail Alert Related Categories
UpgradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
